1. Home
  2. TVTX vs PWP Comparison

TVTX vs PWP Comparison

Compare TVTX & PWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • PWP
  • Stock Information
  • Founded
  • TVTX 2008
  • PWP 2006
  • Country
  • TVTX United States
  • PWP United States
  • Employees
  • TVTX N/A
  • PWP N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • PWP Finance: Consumer Services
  • Sector
  • TVTX Health Care
  • PWP Finance
  • Exchange
  • TVTX Nasdaq
  • PWP Nasdaq
  • Market Cap
  • TVTX 1.6B
  • PWP 1.5B
  • IPO Year
  • TVTX N/A
  • PWP N/A
  • Fundamental
  • Price
  • TVTX $17.51
  • PWP $24.70
  • Analyst Decision
  • TVTX Buy
  • PWP Hold
  • Analyst Count
  • TVTX 13
  • PWP 3
  • Target Price
  • TVTX $23.46
  • PWP $18.83
  • AVG Volume (30 Days)
  • TVTX 1.1M
  • PWP 471.0K
  • Earning Date
  • TVTX 02-13-2025
  • PWP 02-06-2025
  • Dividend Yield
  • TVTX N/A
  • PWP 1.13%
  • EPS Growth
  • TVTX N/A
  • PWP N/A
  • EPS
  • TVTX N/A
  • PWP N/A
  • Revenue
  • TVTX $203,447,000.00
  • PWP $864,769,000.00
  • Revenue This Year
  • TVTX $62.17
  • PWP $35.92
  • Revenue Next Year
  • TVTX $56.38
  • PWP $13.81
  • P/E Ratio
  • TVTX N/A
  • PWP N/A
  • Revenue Growth
  • TVTX 57.08
  • PWP 39.74
  • 52 Week Low
  • TVTX $5.12
  • PWP $10.73
  • 52 Week High
  • TVTX $20.33
  • PWP $26.62
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 39.02
  • PWP 51.50
  • Support Level
  • TVTX $17.27
  • PWP $23.86
  • Resistance Level
  • TVTX $19.20
  • PWP $25.53
  • Average True Range (ATR)
  • TVTX 0.72
  • PWP 0.75
  • MACD
  • TVTX -0.29
  • PWP -0.25
  • Stochastic Oscillator
  • TVTX 3.80
  • PWP 42.32

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

Share on Social Networks: